Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

1. patients who were histologically and cytologically confirmed NSCLC at stage III or IV
2. harbored ALK fusion gene and took crizotinib
3. age:18\~75years
4. Eastern cooperative oncology group performance status(ECOG PS): 0\~2 points
5. the expected lifetime is more than 12 weeks after being recruited

1. patients who also suffered from other malignant tumor
2. uncontrolled systemic diseases,central nervous system (CNS) metastasis
3. clinically active interstitial lung diseases
4. severe liver dysfunction caused by hepatic cirrhosis or hepatitis （Child-Pugh class C, total index score 10-15 points）
5. taking drugs that interact with crizotinib

An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer Patients